Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer.
Steroid 5 alpha-reductase inhibitors (5ARIs) have been approved for use clinically in treatment of benign prostate hyperplasia (BPH) and accompanying lower urinary tract symptoms (LUTS) and have also been evaluated in clinical trials for prevention and treatment of prostate cancer. There are currently two steroidal inhibitors in use, finasteride and dutasteride, both with distinct pharmacokinetic properties. This review will examine the evidence presented by various studies supporting the use of these steroidal inhibitors in the prevention and treatment of prostate disease. Article from the Special issue on Targeted Inhibitors.
Schmidt
Lucy J
LJ
Department of Urology Research, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN 55905, United States.
Tindall
Donald J
DJ
D058891:5-alpha Reductase Inhibitors / Q000737:chemistry / Q000627:therapeutic use*; D001378:Azasteroids / Q000737:chemistry / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D000068538:Dutasteride; D018120:Finasteride / Q000737:chemistry / Q000627:therapeutic use; D006801:Humans; D008297:Male; D015394:Molecular Structure; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D058891:5-alpha Reductase Inhibitors; D001378:Azasteroids; D018120:Finasteride; D000068538:Dutasteride